Browse the corpus

Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related deaths in women. Early detection through screening can significantly reduce both morbidity and mortality. Screening recommendations distinguish between women at average and high risk for developing breast cancer, as this risk stratification guides the selection of screening methods and timing. Most major guidelines recommend starting routine mammography at age 40 for women at average risk. Although the frequency of screening—either annually or biennially—varies among guidelines, the overall trend is toward increased surveillance due to its potential to save lives. Clinical breast examinations are recommended every 1 to 3 years for women aged 25 to 39 and annually for women aged 40 or older. Screening typically continues until the patient’s life expectancy is less than age 10, with the decision to discontinue based on individual health status and overall life expectancy. This activity reviews breast cancer screening for average-risk patients and offers healthcare professionals guidance on assessing breast cancer risk, conducting appropriate screenings, and implementing interprofessional management strategies to enhance patient outcomes. This activity also highlights the significance of multidisciplinary collaboration among healthcare providers to ensure comprehensive and personalized care for patients with varying levels of breast cancer risk. Objectives: Identify the criteria that classify patients as average-risk or high-risk patients for breast cancer to ensure appropriate screening practices. Implement evidence-based practices for breast cancer screening, ensuring adherence to current guidelines and recommendations. Select appropriate imaging modalities, such as MRI and mammography, based on patient risk factors and preferences. Collaborate with an interprofessional healthcare team to enhance the overall management of breast cancer screening and follow-up care for patients. Access free multiple choice questions on this topic.

Breast cancer is the most common malignancy in women,[1] and it is the most prevalent non-skin cancer. Breast cancer is also considered the second leading cause of cancer-related deaths in women. Stage IV breast cancer currently has no curative treatment and is managed with palliative care. Early detection of tumors significantly reduces morbidity and mortality. The primary challenge lies in determining who should be screened and when. Additionally, as our understanding of the pathophysiology of breast cancer develops, treatment decisions are shifting away from focusing solely on tumor size and extent. Increasingly, the incorporation of genetic and biological characteristics is being used to guide prognosis and treatment.[2] In addition to self-breast examinations, the primary screening methods include clinical breast evaluations and imaging techniques such as mammography, ultrasonography, and magnetic resonance imaging (MRI). Multiple randomized studies have established that routine screening mammography should be offered to women aged 50 to 69. Historically, the recommendation for routine mammograms for women aged 40 to 49 or those aged 70 or older has been debated. However, the latest guidelines from the United States Preventive Services Task Force (USPSTF), the American College of Obstetricians and Gynecologists (ACOG), the American Society of Breast Surgeons (ASBrS), and the National Comprehensive Cancer Network (NCCN) now advocate starting routine mammograms at age 40.[3] The frequency of screening remains a topic of debate, with some groups recommending annual screening for average-risk individuals while others advocate for biennial screening. Overall, there has been a trend toward expanded screening, as breast cancer detection at early and treatable stages has saved countless lives. Differentiating between average-risk and high-risk patients is crucial for optimizing patient outcomes, as screening recommendations vary for these populations. Our growing understanding of oncogenic genetic mutations and other breast cancer risk factors has led to the development of several breast cancer risk prediction models, such as the Gail model and the Tyrer-Cuzick model. These models facilitate the stratification of breast cancer screening based on an individual's lifetime risk of developing the disease.[4]

The frequency of screening remains a topic of debate, with some groups recommending annual screening for average-risk individuals while others advocate for biennial screening. Overall, there has been a trend toward expanded screening, as breast cancer detection at early and treatable stages has saved countless lives. Differentiating between average-risk and high-risk patients is crucial for optimizing patient outcomes, as screening recommendations vary for these populations. Our growing understanding of oncogenic genetic mutations and other breast cancer risk factors has led to the development of several breast cancer risk prediction models, such as the Gail model and the Tyrer-Cuzick model. These models facilitate the stratification of breast cancer screening based on an individual's lifetime risk of developing the disease.[4] In addition to mammography, ultrasonography and breast MRI are recommended for screening for high-risk women.[5] High-risk patients, symptomatic individuals, and breast cancer survivors should be identified and referred to a breast center for evaluation by a breast cancer specialist to receive appropriate screening recommendations. Please see StatPearls' companion resource, "Breast Cancer," for more information on high-risk factors for breast cancer.

Mammography has its limitations as a screening imaging method. Research indicates that it is less sensitive in detecting cancer in dense breast tissue, which can result in false-negative outcomes and the potential for missed cancers, if present. Some breast cancers may be mammographically occult, failing to appear on traditional mammograms. Thus, it is essential to conduct imaging alongside a physical examination by a healthcare clinician. Further diagnostic imaging, such as MRI or ultrasound, should be ordered when discrepancies arise. Additionally, high-risk patients should be screened appropriately, often utilizing MRI for more accurate detection. Increased treatment interventions are associated with screening, which may not always be effective or necessary. Individuals who undergo screening are more likely to experience surgery and radiation therapy. Overscreening can have negative consequences for patients, including economic, psychological, cosmetic, physical, and productivity-related harm. The overall lifetime radiation exposure increases with the age of initiation, frequency, and cessation of screening, as women are exposed to approximately 3.7 mGy per digital mammogram. This raises the risk of radiation-induced breast cancer to 125 cases per 100,000 women aged 40 to 74, potentially leading to an increase in deaths attributed to breast cancer screening. Ultrasonography is generally considered a highly operator-dependent modality and supplemental screening test that requires a skilled practitioner, high-quality examination, and state-of-the-art equipment. Based on the findings from various studies, a prospective, multicenter study is warranted to further investigate the role of this imaging modality in breast cancer screening.[16]

Screening average-risk breast cancer patients necessitates a collaborative and interprofessional approach to enhance patient-centered care, improve outcomes, and ensure safety. Physicians, advanced practitioners, nurses, pharmacists, radiologists, and technicians must work together to balance the benefits and risks of screening. Clinicians are responsible for identifying risk factors and providing appropriate screening based on age, breast density, and family history. Effective counseling, especially for patients with genetic predispositions, requires shared decision-making. Radiologists and technicians must skillfully perform and interpret imaging to minimize false positives and negatives. This coordinated effort fosters a comprehensive care strategy that improves diagnosis and patient outcomes.